Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction

Completed · Phase 1/Phase 2

Conditions studied: Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient)

In brief

This research study is for liver transplant recipients and their respective living donors. The purpose of this study is: 1. To see if it is safe for liver recipients to receive one dose of donor reactive T regulatory cells (Tregs) 2. To see if the Tregs allows a liver recipient to take less, or completely stop medications normally taken after receiving an organ transplant.

Key facts

Study ID

NCT02474199

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

15

Starts

2016-06-06

Expected to finish

2019-12-16

Last updated by the study team

2021-02-09

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California at San Francisco — San Francisco, California, United States
• Northwestern University Comprehensive Transplant Ctr — Chicago, Illinois, United States
• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.